Friday - July 25, 2025
ENGLEWOOD, Colo., Aug. 9, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced the addition of three new therapy products centered around pain management. The new products include Zynex Pro Thoracic Lumbar Sacral Orthosis ("TLSO"), a dual-purpose back brace for the mid and lower spine; Zynex Pro Wrist, a wrist brace for a broad spectrum of wrist-related pain management including carpal tunnel syndrome; and Zynex Cryoheat, a localized cold or hot fluid therapy system for home or hospital use.
Thomas Sandgaard, Founder and CEO, explains, "As we continue to build out our sales force in pain management, we are continually looking to add to our product suite in complementary ways. Combining these products with our industry-leading prescription strength pain management device, the NexWave builds upon our holistic, non-invasive approach to pain management."
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
ZYXI@mzgroup.us
+949 694 9594
Last Trade: | US$2.53 |
Daily Change: | 0.03 1.20 |
Daily Volume: | 141,605 |
Market Cap: | US$76.510M |
June 30, 2025 April 29, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load